Andrea Russo1, Raffaele Turano2, Francesco Morescalchi2, Elena Gambicorti2, Anna Cancarini2, Sarah Duse2, Ciro Costagliola3, Francesco Semeraro2. 1. Eye Clinic, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazzale Spedale Civili, 1, 25100, Brescia, Italy. dott.andrea.russo@me.com. 2. Eye Clinic, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazzale Spedale Civili, 1, 25100, Brescia, Italy. 3. Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
Abstract
PURPOSE: To compare visual and anatomical outcomes between half-dose photodynamic therapy (hd-PDT) and 689 nm laser therapy (689-LT) in chronic central serous chorioretinopathy (CSC). METHODS:Forty eyes of 40 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive either hd-PDT or 689-LT delivering 95 J/cm2 via an intensity application of 805 mW/cm2 over 118 s. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between the two treatment groups. RESULTS:Mean CSC duration was 17.1 ± 6.66 weeks and 18.7 ± 7.46 weeks in the hd-PDT and 689-LT groups respectively. Both groups showed significant BCVA improvements, as well as reductions in central retinal and subfoveal choroidal thickness. Although hd-PDT led to a faster reduction in central retinal thickness, no significant differences were recorded between groups for any other measured parameter at any time point. Complete photoreceptor recovery was observed in eight and seven eyes in the hd-PDT and 689-LT groups respectively. CONCLUSIONS: Both hd-PDT and 689-LT were effective at treating chronic CSC. Further studies are warranted to evaluate long-term safety and efficacy.
RCT Entities:
PURPOSE: To compare visual and anatomical outcomes between half-dose photodynamic therapy (hd-PDT) and 689 nm laser therapy (689-LT) in chronic central serous chorioretinopathy (CSC). METHODS: Forty eyes of 40 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive either hd-PDT or 689-LT delivering 95 J/cm2 via an intensity application of 805 mW/cm2 over 118 s. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between the two treatment groups. RESULTS: Mean CSC duration was 17.1 ± 6.66 weeks and 18.7 ± 7.46 weeks in the hd-PDT and 689-LT groups respectively. Both groups showed significant BCVA improvements, as well as reductions in central retinal and subfoveal choroidal thickness. Although hd-PDT led to a faster reduction in central retinal thickness, no significant differences were recorded between groups for any other measured parameter at any time point. Complete photoreceptor recovery was observed in eight and seven eyes in the hd-PDT and 689-LT groups respectively. CONCLUSIONS: Both hd-PDT and 689-LT were effective at treating chronic CSC. Further studies are warranted to evaluate long-term safety and efficacy.
Authors: Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-02-07 Impact factor: 3.117
Authors: Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; Emily W H Tang; David T L Liu; Dennis S C Lam Journal: Retina Date: 2008-01 Impact factor: 4.256
Authors: Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Małgorzata Kneba; Andrzej Grzybowski Journal: J Clin Med Date: 2019-09-06 Impact factor: 4.241